Literature DB >> 22574684

Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.

Nian Xiong1, Xi Long, Jing Xiong, Min Jia, Chunnuan Chen, Jinsha Huang, Devina Ghoorah, Xiangquan Kong, Zhicheng Lin, Tao Wang.   

Abstract

The etiology of Parkinson's disease (PD) is attributed to both environmental and genetic factors. The development of PD reportedly involves mitochondrial impairment, oxidative stress, α-synuclein aggregation, dysfunctional protein degradation, glutamate toxicity, calcium overloading, inflammation and loss of neurotrophic factors. Based on a link between mitochondrial dysfunction and pesticide exposure, many laboratories, including ours, have recently developed parkinsonian models by utilization of rotenone, a well-known mitochondrial complex I inhibitor. Rotenone models for PD appear to mimic most clinical features of idiopathic PD and recapitulate the slow and progressive loss of dopaminergic (DA) neurons and the Lewy body formation in the nigral-striatal system. Notably, potential human parkinsonian pathogenetic and pathophysiological mechanisms have been revealed through these models. In this review, we summarized various rotenone-based models for PD and discussed the implied etiology of and treatment for PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22574684     DOI: 10.3109/10408444.2012.680431

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  49 in total

1.  Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.

Authors:  Miguel Mendivil-Perez; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio
Journal:  Neurochem Res       Date:  2016-07-09       Impact factor: 3.996

2.  A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.

Authors:  Christophe Antczak; Boyoung Wee; Constantin Radu; Bhavneet Bhinder; Eric C Holland; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2013-08-30       Impact factor: 1.738

3.  α-Arbutin Protects Against Parkinson's Disease-Associated Mitochondrial Dysfunction In Vitro and In Vivo.

Authors:  Yaqi Ding; Deqin Kong; Tong Zhou; Nai-di Yang; Chenqi Xin; Jiajia Xu; Qi Wang; Hang Zhang; Qiong Wu; Xiaomei Lu; Kahleong Lim; Bo Ma; Chengwu Zhang; Lin Li; Wei Huang
Journal:  Neuromolecular Med       Date:  2019-08-10       Impact factor: 3.843

Review 4.  Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms.

Authors:  Arthi Kanthasamy; Huajun Jin; Adhithiya Charli; Anantharam Vellareddy; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

5.  The Interaction of Mitochondrial Biogenesis and Fission/Fusion Mediated by PGC-1α Regulates Rotenone-Induced Dopaminergic Neurotoxicity.

Authors:  Kaige Peng; Likui Yang; Jian Wang; Feng Ye; Guorong Dan; Yuanpeng Zhao; Ying Cai; Zhihong Cui; Lin Ao; Jinyi Liu; Zhongmin Zou; Yan Sai; Jia Cao
Journal:  Mol Neurobiol       Date:  2016-06-07       Impact factor: 5.590

6.  Combined oral supplementation of fish oil and quercetin enhances neuroprotection in a chronic rotenone rat model: relevance to Parkinson's disease.

Authors:  K M Denny Joseph
Journal:  Neurochem Res       Date:  2015-02-17       Impact factor: 3.996

Review 7.  Neurobehavioural Changes in a Hemiparkinsonian Rat Model Induced by Rotenone.

Authors:  Sukala Puthuparambil Maniyath; Narayanan Solaiappan; Muthusamy Rathinasamy
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.

Authors:  Hiroharu Maegawa; Hitoshi Niwa
Journal:  Methods Mol Biol       Date:  2021

9.  hVMAT2: A Target of Individualized Medication for Parkinson's Disease.

Authors:  Nian Xiong; Nuomin Li; Eden Martin; Jinlong Yu; Jie Li; Jing Liu; David Yue-Wei Lee; Ole Isacson; Jeffery Vance; Hong Qing; Tao Wang; Zhicheng Lin
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

Review 10.  Induced pluripotent stem cells and Parkinson's disease: modelling and treatment.

Authors:  Xiaoyun Xu; Jinsha Huang; Jie Li; Ling Liu; Chao Han; Yan Shen; Guoxin Zhang; Haiyang Jiang; Zhicheng Lin; Nian Xiong; Tao Wang
Journal:  Cell Prolif       Date:  2016-01-08       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.